Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3720-3724

  Amendola, A ^a   Tanzi, E ^a   Zappa, A ^a   Colzani, D ^a   Boschini, A ^b   Musher, D M ^c   Zanetti, A R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b San Patrignano Community   (Italy)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD4+ counts; HIV 1 load; Pneumococcal polysaccharide vaccine

Indexed keywords

ANTIBODY; ANTIGEN; BACTERIAL VACCINE; CD4 ANTIGEN; POLYSACCHARIDE; POLYSACCHARIDE VACCINE; VIRUS DNA; VIRUS RNA; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIAL POLYSACCHARIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PNEUMOCOCCUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOSE CALCULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GEOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RNA ANALYSIS; SAMPLING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; BIOSYNTHESIS; BLOOD; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PROVIRUS; SERODIAGNOSIS; SUBSTANCE ABUSE; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; PROVIRUSES; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 0036838639     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00357-2     Document Type: Article

References (24)

1. Janoff E.N., Breiman R.F., Daley C.L., Hopewell P.C. Pneumococcal disease during HIV infection. Epidemiologic, clinical and immunologic perspectives. Ann. Intern. Med. 117:1992;314-324.
2. Osmond D.H., Chin D.P., Glassroth J.et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Clin. Infect. Dis. 29:1999;536-543.
3. French N., Nakiyingi J., Carpenter L.M.et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 355:2000;2106-2111.
4. Fedson D.S., Watson M. Pneumococcal vaccine and HIV-1 infection. Lancet. 356:2000;1272-1273.
5. Breiman R.F., Keller D.W., Phelan M.A.et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV infected patients. Arch. Intern. Med. 160:2000;2633-2638.
6. Lindenburg C.E., Langendam M.W., Benthem B.H., Miedema F., Coutinho R.A. No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. AIDS. 15:2001;1315-1317.
7. Rodriguez-Barradas M.C., Musher D.M., Lahart C.et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of HIV infected subjects with 23-valent pneumococcal vaccine. J. Infect. Dis. 165:1992;553-556.
8. Weiss P.J., Wallace M.R., Oldfield E.C. III, O'Brien J., Janoff E.N. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J. Infect. Dis. 171:1995;1217-1222.
9. Staprans S.I., Hamilton B.L., Follansbee S.E.et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J. Exp. Med. 182:1995;1727-1737.
10. Brichacek B., Swindells S., Janoff E.N., Pirruccello S., Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174:1996;1191-1199.
11. Centers for Disease Control and Prevention 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep 1993;41(RR-17):1-19.
12. Musher D.M., Groover J.E., Rowland J.M.et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis. 17:1993;66-73.
13. Musher D.M., Phan H.M., Watson D.A., Baughn R.E. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J. Infect. Dis. 182:2000;158-167.
14. Swanson P., Harris B.J., Holzmayer V., Devare S.G., Schochetman G., Hackett J. Jr. Quantification of HIV-1 group M (subtype A-G) and group O by the LCx HIV RNA quantitative assay. J. Virol. Methods. 89:2000;97-108.
15. Amendola A., Boschini A., Colzani D.et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J. Med. Virol. 65:2001;644-648.
16. Stoneburner R.L., Des Jarlais D.C.et al. A larger spectrum of severe HIV-related disease in intravenous drug users in New York City. Science. 242:1988;916-919.
17. Drucker E., Webber M.P., McMaster P., Vermund S.H. Increasing rate of pneumonia hospitalizations in the Bronx: a sentinel indicator for human immunodeficiency virus. Int. J. Epidemiol. 18:1989;926-933.
18. Selwyn P.A., Hartel D., Wasserman W., Drucker E. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am. J. Public Health. 79:1989;1358-1362.
19. Redd S.C., Rutherford G.W. III, Sande M.A.et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J. Infect. Dis. 162:1990;1012-1017.
20. Boschini A., Smacchia C., Di Fine M.et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin. Infect. Dis. 23:1996;107-113.
21. Mascart-Lemone F., Gèrard M., Libin M.et al. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J. Infect. Dis. 172:1995;1253-1260.
22. Klein R.S., Selwyn P.A., Maude D., Pollard C., Freeman K., Schiffman G. Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus. J. Infect. Dis. 160:1989;826-831.
23. Huang K.L., Ruben F.L., Rinaldo C.R. Jr., Kingsley L., Lyter D.W., Ho M. Antibody responses after influenza and pneumococcal immunization in HIV infected homosexual men. JAMA. 257:1987;2047-2050.
24. Kroon F.P., van Dissel J.T., Ravensbergen E., Nibbering P.H., van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV infected adults. Vaccine. 19:2000;886-894.